

# Curriculum Vitae

**NAME:** Jeehoon Kang, MD (E-mail: medikang@gmail.com)

**Birthdate:** October 26, 1980

## EDUCATION

1996 – 1999 Deajon Science High School, Daejon Korea

2000 - 2004 Seoul National University, College of Natural Science, Biomedical Science (BS)

2004 - 2008 Seoul National University, College of Medicine (MD)

2011 – 2017 Seoul National University, Department of Molecular Medicine and Biopharmaceutical Sciences. (PhD Candidate)

## TRAINING

2008.2 – 2009.2 Internship, Seoul National University Hospital, Seoul, Korea

2009.3 – 2013.2 Residency in Internal Medicine, Seoul National University Hospital, Seoul, Korea

2013.3 – 2016.4 Military Medical Officer, Captain

2016.5 – 2018.3 Clinical Fellowship in Cardiology, Seoul National University Hospital, Seoul, Korea

2018.4 - Assistant professor, Department of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, Seoul, Korea

2020.3 - Assistant professor, Department of Critical Care Medicine, Seoul

National University Hospital, Seoul, Korea

2023.3 - Associate professor, Department of Critical Care Medicine, Seoul  
National University Hospital, Seoul, Korea

### **AWARDS AND RECOGNITIONS**

2012	Best Speaker at the 63th Korean Internal Medicine Conference
2013	Best Medical Officer, 2013
2016	Best Speaker at the 12th KSIC International Conference
2017	Best Speaker at the 13th KSIC International Conference
2019	Young investigator Award, TCTAP 2019
2021	Doosan Yonkang Academic award
2022	Hamchoon Academic award

### **LICENSE AND MEMBERSHIP**

Korean Medical Licence	2008
Board Certification in Internal Medicine	2013
Board Certification in Cardiovascular Medicine	2017
Board Certification in Critical Care Medicine	2020

**PUBLICATIONS (Asterisk for publications as FIRST, CO-FIRST or CORRESPONDING author)**

**Kang J\***, Rizas KD, Park KW, Chung J, van den Broek W, Claassens DMF, Choo EH, Aradi D, Massberg S, Hwang D, Han JK, Yang HM, Kang HJ, Chang K, Ten Berg JM, Sibbing D, Koo BK, Kim HS. Dual antiplatelet therapy de-escalation in acute coronary syndrome: an individual patient meta-analysis. *Eur Heart J*. 2023 Apr 17;44(15):1360-1370. doi: 10.1093/eurheartj/ehac829.

Kim JH, Franchin L, Hong SJ, Cha JJ, Lim S, Joo HJ, Park JH, Yu CW, Lim DS, Filippo O, Gwon HC, Piroli F, Kim HS, Wanha W, Choi KH, Song YB, Patti G, Nam CW, Bruno F, Kang J, Bocchino PP, De Ferrari GM, Koo BK, D'Ascenzo F. Two-Year clinical outcomes after coronary bifurcation stenting in older patients from Korea and Italy. *Front Cardiovasc Med*. 2023 Mar 23;10:1106594. doi: 10.3389/fcvm.2023.1106594. eCollection 2023.

Yun JP, **Kang J\***, Park KW, Park K, Hwang D, Han JK, Yang HM, Kang HJ, Koo BK, Chae IH, Moon KW, Park HW, Won KB, Jeon DW, Han KR, Choi SW, Ryu JK, Jeong MH, Kim HS. Prasugrel-Based De-Escalation in Patients With Acute Coronary Syndrome According to Renal Function. *JACC Asia*. 2023 Jan 10;3(1):51-61. doi: 10.1016/j.jacasi.2022.09.013. eCollection 2023 Feb.

Han JK, Hwang D, Yang S, Park SH, Kang J, Yang HM, Park KW, Kang HJ, Koo BK, Hur SH, Kim W, Kim SY, Park SH, Han SH, Kim SH, Shin S, Kim YH, Park K, Lee N, Lee SJ, Kim JW, Kim HS. Comparison Of 3-6 Month Versus 12 Month Dual Antiplatelet Therapy After Coronary Intervention Using the Contemporary Drug-eluting Stents With Ultrathin Struts: The HOST-IDEA Randomized Clinical Trial. *Circulation*. 2023 Mar 5. doi: 10.1161/CIRCULATIONAHA.123.064264.

Rismiati H, Lee KS, Kang J, Cho HJ, Lee HY. The role of discharge checklist in guideline-directed medical therapy for heart failure patients. *Korean J Intern Med*. 2023 Mar;38(2):195-206. doi: 10.3904/kjim.2022.326.

Lee KS, Park KH, Park KW, Rha SW, Hwang D, Kang J, Han JK, Yang HM, Kang HJ, Koo BK, Lee NH, Rhew JY, Chun KJ, Lim YH, Bong JM, Bae JW, Lee BK, Kim SY, Shin WY, Lim HS, Park K, Kim HS. Prasugrel dose de-escalation in diabetic patients with acute coronary syndrome receiving percutaneous coronary intervention: results from the HOST-REDUCE-POLYTECH-ACS trial. *Eur Heart J Cardiovasc Pharmacother*. 2023 Apr 10;9(3):262-270. doi: 10.1093/ehjcvp/pvad008.

Ahn HJ, **Kang J\***, Lee SR, Park JJ, Lee HY, Choi DJ, Cho HJ. Neutrophil-to-lymphocyte ratio as a predictor of in-hospital complications and overall mortality in Takotsubo syndrome preceded by physical triggers. *BMC Cardiovasc Disord*. 2023 Jan 27;23(1):51. doi: 10.1186/s12872-023-03078-1.

**Kang J\***, Han JK, Yang HM, Park KW, Kang HJ, Koo BK, Choo EH, Lee JY, Park SD, Lim YH, Kim HM, Heo JH, Kim HS. Real-world evidence of switching P2Y12 receptor-inhibiting therapies to prasugrel after PCI in patients with ACS: results from EFF-K registry. *BMC Cardiovasc Disord.* 2023 Jan 9;23(1):6. doi: 10.1186/s12872-022-03034-5.

**Kang J\***, Bruno F\*, Rhee TM, De Luca L, Han JK, de Filippo O, Yang HM, Mattesini A, Park KW, Truffa A, Kim HS, Wojciech W, Gwon HC, Gili S, Chun WJ, Helft G, Hur SH, Cortese B, Han SH, Escaned J, Song YB, Chieffo A, Choi KH, Gallone G, Doh JH, De Ferrari G, Hong SJ, Quadri G, Nam CW, Koo BK, D'Ascenzo F. Impact of Clinical and Lesion Features on Outcomes After Percutaneous Coronary Intervention in Bifurcation Lesions. *JACC Asia.* 2022 Sep 20;2(5):607-618.

Koo BK\*, Hu X\*, **Kang J\***, Zhang J, Jiang J, Hahn JY, Nam CW, Doh JH, Lee BK, Kim W, Huang J, Jiang F, Zhou H, Chen P, Tang L, Jiang W, Chen X, He W, Ahn SG, Yoon MH, Kim U, Lee JM, Hwang D, Ki YJ, Shin ES, Kim HS, Tahk SJ, Wang J; FLAVOUR Investigators. Fractional Flow Reserve or Intravascular Ultrasonography to Guide PCI. *N Engl J Med.* 2022 Sep 1;387(9):779-789.

\* Equal Contribution

Kim HS, Kang J. The unsolved issue with limited evidence: antiplatelet therapy during the chronic maintenance period after percutaneous coronary intervention. *EuroIntervention.* 2022 Aug 5;18(5):e355-e356.

Gallone G\*, **Kang J\***, Bruno F, Han JK, De Filippo O, Yang HM, Doronzo M, Park KW, Mittone G, Kang HJ, Parma R, Gwon HC, Cerrato E, Chun WJ, Smolka G, Hur SH, Helft G, Han SH, Muscoli S, Song YB, Figini F, Choi KH, Boccuzzi G, Hong SJ, Trabattoni D, Nam CW, Giammaria M, Kim HS, Conrotto F, Escaned J, Di Mario C, D'Ascenzo F, Koo BK, de Ferrari GM. Impact of Left Ventricular Ejection Fraction on Procedural and Long-Term Outcomes of Bifurcation Percutaneous Coronary Intervention. *Am J Cardiol.* 2022 Jun 1;172:18-25.

\* Equal Contribution

Cha JJ, Hong SJ, Kim JH, Lim S, Joo HJ, Park JH, Yu CW, Kang J, Kim HS, Gwon HC, Chun WJ, Hur SH, Han SH, Rha SW, Chae IH, Jeong JO, Heo JH, Yoon J, Park JS, Hong MK, Doh JH, Cha KS, Kim DI, Lee SY, Chang K, Hwang BH, Choi SY, Jeong MH, Song YB, Choi KH, Nam CW, Koo BK, Lim DS. Bifurcation strategies using second-generation drug-eluting stents on clinical outcomes in diabetic patients. *Front Cardiovasc Med.* 2022 Dec 21;9:1018802.

Palmerini T, Bruno AG, Gasparini M, Rizzello G, Kim HS, Kang J, Park KW, Hahn JY, Song YB, Gwon HC, Choo EH, Park MW, Kim CJ, Chang K, Cuisset T, Taglieri N, Kim BK, Jang Y, Nardi E, Saia F, Orzalkiewicz M, Chietera F, Ghetti G, Galiè N, Stone GW. Reduced Mortality With Antiplatelet Therapy Deescalation After Percutaneous Coronary Intervention in Acute Coronary Syndromes: A Meta-Analysis.

Circ Cardiovasc Interv. 2022 Nov;15(11):906-914.

Kim EC, Kim SH, Lee Y, Sohn SH, Choi JW, Kang J, Han JK, Kim KH, Kim HS, Hwang HY. The Impact of Surgical versus Transcatheter Aortic Valve Replacement on Postprocedural Acute Kidney Injury in Patients with Chronic Kidney Disease. *J Chest Surg.* 2022 Dec 5;55(6):435-441.

Won KB, Shin ES, Kang J, Yang HM, Park KW, Han KR, Moon KW, Oh SK, Kim U, Rhee MY, Kim DI, Kim SY, Lee SY, Han JK, Koo BK, Kim HS. Body Mass Index and Major Adverse Events During Chronic Antiplatelet Monotherapy After Percutaneous Coronary Intervention With Drug-Eluting Stents - Results From the HOST-EXAM Trial. *Circ J.* 2023 Jan 25;87(2):268-276.

Park CS, Yang HM, Kang J, Han JK, Park KW, Kang HJ, Koo BK, Seung KB, Cha KS, Seong IW, Rha SW, Jeong MH, Kim HS. Long-term use of renin-angiotensin-system inhibitors after acute myocardial infarction is not associated with survival benefits: Analysis of data from the Korean acute myocardial infarction registry-national institutes of health registry. *Front Cardiovasc Med.* 2022 Aug 31;9:994419.

Hwang D, Lim YH, Park KW, Chun KJ, Han JK, Yang HM, Kang HJ, Koo BK, Kang J, Cho YK, Hong SJ, Kim S, Jo SH, Kim YH, Kim W, Lee SY, Kim YD, Oh SK, Lee JH, Kim HS; HOST-RP-ACS investigators. Prasugrel Dose De-escalation Therapy After Complex Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome: A Post Hoc Analysis From the HOST-REDUCE-POLYTECH-ACS Trial. *JAMA Cardiol.* 2022 Apr 1;7(4):418-426.

Ahmed TAN, Ki YJ, Choi YJ, El-Naggar HM, Kang J, Han JK, Yang HM, Park KW, Kang HJ, Koo BK, Kim HS. Impact of Systemic Inflammatory Response Syndrome on Clinical, Echocardiographic, and Computed Tomographic Outcomes Among Patients Undergoing Transcatheter Aortic Valve Implantation. *Front Cardiovasc Med.* 2022 Feb 9;8:746774.

Park J, Jung JH, Choi EK, Lee SW, Kwon S, Lee SR, Kang J, Han KD, Park KW, Oh S, Lip GYH. Comparison of early clinical outcomes between dual antiplatelet therapy and triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. *PLoS One.* 2022 Feb 25;17(2):e0264538.

Ki YJ, Lee BK, Park KW, Bae JW, Hwang D, Kang J, Han JK, Yang HM, Kang HJ, Koo BK, Kim DB, Chae IH, Moon KW, Park HW, Won KB, Jeon DW, Han KR, Choi SW, Ryu JK, Jeong MH, Cha KS, Kim HS; HOST-RP-ACS investigators. Prasugrel-based De-Escalation of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With STEMI. *Korean Circ J.* 2022 Apr;52(4):304-319.

Lee SR, Jung JH, Choi EK, Lee SW, Kwon S, Park JS, Kang J, Han KD, Park KW, Oh S, Lip GYH. Net clinical benefit of antithrombotic therapy for atrial fibrillation patients with stable coronary artery disease. *Front Cardiovasc Med*. 2022 Aug 22;9:991293.

Hwang D, Lim HS, Park KW, Shin WY, Kang J, Han JK, Yang HM, Kang HJ, Koo BK, Cho YK, Hong SJ, Kim S, Jo SH, Kim YH, Kim W, Lee SY, Oh SK, Kim DB, Kim HS. Durable polymer versus biodegradable polymer drug-eluting stents in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention: a post hoc analysis of the HOST-REDUCE-POLYTECH-ACS trial. *EuroIntervention*. 2022 Dec 2;18(11):e910-e919.

Park J, Han JK, Kang J, Chae IH, Lee SY, Choi YJ, Rhew JY, Rha SW, Shin ES, Woo SI, Lee HC, Chun KJ, Kim D, Jeong JO, Bae JW, Yang HM, Park KW, Kang HJ, Koo BK, Kim HS. The Clinical Impact of  $\beta$ -Blocker Therapy on Patients With Chronic Coronary Artery Disease After Percutaneous Coronary Intervention. *Korean Circ J*. 2022 Jul;52(7):544-555.

Hwang D, Park J, Yang HM, Yang S, Kang J, Han JK, Park KW, Kang HJ, Koo BK, Kim HS. Angiographic complete revascularization versus incomplete revascularization in patients with diabetes mellitus. *Cardiovasc Diabetol*. 2022 Apr 19;21(1):56. doi: 10.1186/s12933-022-01488-7.

Park SH, **Kang J\*** Kim TJ, Lee HY, Cho HJ, Lee SM. Current status of the rapid response system and early warning score: a survey-based analysis. *Acute Crit Care*. 2022 Nov;37(4):687-689.

Chung J, **Kang J\***, Lee HY, Sohn SH, Hwang HY, Cho HJ. Intractable right coronary artery spasm in the early postoperative period after heart transplantation: a case report. *Korean J Transplant*. 2022 Jun 30;36(2):154-158. doi: 10.4285/kjt.22.0006. Epub 2022 Jun 13.

De Filippo O, **Kang J\***, Bruno F, Han JK, Saglietto A, Yang HM, Patti G, Park KW, Parma R, Kim HS, De Luca L, Gwon HC, Iannaccone M, Chun WJ, Smolka G, Hur SH, Cerrato E, Han SH, di Mario C, Song YB, Escaned J, Choi KH, Helft G, Doh JH, Truffa Giachet A, Hong SJ, Muscoli S, Nam CW, Gallone G, Capodanno D, Trabattoni D, Imori Y, Dusi V, Cortese B, Montefusco A, Conrotto F, Colonnelli I, Sheiban I, de Ferrari GM, Koo BK, D'Ascenzo F. Benefit of Extended Dual Antiplatelet Therapy Duration in Acute Coronary Syndrome Patients Treated with Drug Eluting Stents for Coronary Bifurcation Lesions (from the BIFURCAT Registry). *Am J Cardiol*. 2021 Oct 1;156:16-23. doi: 10.1016/j.amjcard.2021.07.005. Epub 2021 Aug 2.

\* Equal contribution

Chung H, Kim SY, **Kang J**, Phi JH, Kim WH, Yang SW, Kwon HW, Lee SY, Kim GB, Bae EJ, Song MK,

Chae JH. Siblings With Familial Dwarfism Presenting With Acute Myocardial Infarction at Adolescence. *JACC Case Rep.* 2021 May 19;3(5):795-800. doi: 10.1016/j.jaccas.2021.03.015.

Franchin L, Kang J\*, De Filippo O, Gwon HC, Piroli F, Kim HS, Wañha W, Song YB, Patti G, Hong SJ, Bruno F, Bocchino PP, De Ferrari GM, Koo BK, D'Ascenzo F. Incidence and Predictors of Stent Thrombosis in Patients Treated with Stents for Coronary Bifurcation Narrowing (From the BIFURCAT Registry). *Am J Cardiol.* 2021 Oct 1;156:24-31. doi: 10.1016/j.amjcard.2021.06.031.

**\* Equal contribution**

**Kang J\***, Han JK, Yang HM, Park KW, Kang HJ, Gwon HC, Chun WJ, Hur SH, Han SH, Rha SW, Chae IH, Jeong JO, Heo JH, Yoon J, Lim DS, Park JS, Hong MK, Doh JH, Cha KS, Kim DI, Lee SY, Chang K, Hwang BH, Choi SY, Jeong MH, Song YB, Choi KH, Hong SJ, Nam CW, Koo BK, Kim HS. Comparison of 2-Stenting Strategies Depending on Sequence or Technique for Bifurcation Lesions in the Second-Generation Drug-Eluting Stent Era - Analysis From the COBIS (Coronary Bifurcation Stenting) III Registry. *Circ J.* 2021 Jun 2. doi: 10.1253/circj.CJ-20-0999.

Koo BK, Kang J\*, Park KW, Rhee TM, Yang HM, Won KB, Rha SW, Bae JW, Lee NH, Hur SH, Yoon J, Park TH, Kim BS, Lim SW, Cho YH, Jeon DW, Kim SH, Han JK, Shin ES, Kim HS; HOST-EXAM investigators. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial. *Lancet.* 2021 Jun 26;397(10293):2487-2496. doi: 10.1016/S0140-6736(21)01063-1. Epub 2021 May 16.

**\* Equal contribution**

Ki YJ, **Kang J**, Yang HM, Woo Park K, Kang HJ, Koo BK, Cho MC, Kim CJ, Ahn Y, Jeong MH, Han JK, Kim HS; investigators for Korea Acute Myocardial Infarction Registry-National Institute of Health (KAMIR-NIH). Immediate Compared With Delayed Percutaneous Coronary Intervention for Patients With ST-Segment-Elevation Myocardial Infarction Presenting  $\geq 12$  Hours After Symptom Onset Is Not Associated With Improved Clinical Outcome. *Circ Cardiovasc Interv.* 2021 May;14(5):e009863.

Lee HS, Park KW, **Kang J**, Han JK, Kim HS. De-escalation of Prasugrel Results in Higher Percentage of Patients within Optimal Range of Platelet Reactivity: Analysis from the HOST-REDUCE-POLYTECH-ACS Trial. *Thromb Haemost.* 2021 Apr 30. doi: 10.1055/a-1496-7987.

Park J, Jung JH, Choi EK, Lee SW, Kwon S, Lee SR, **Kang J**, Han KD, Park KW, Oh S, Lip GYH. Longitudinal Patterns in Antithrombotic Therapy in Patients with Atrial Fibrillation after Percutaneous Coronary Intervention in the Non-Vitamin K Oral Anticoagulant Era: A Nationwide Population-Based Study. *J Clin Med.* 2021 Apr 4;10(7):1505. doi: 10.3390/jcm10071505.

Park CS, Yang HM, Ki YJ, **Kang J**, Han JK, Park KW, Kang HJ, Koo BK, Kim CJ, Cho MC, Kim YJ, Chae SC, Jeong MH, Kim HS; KAMIR-NIH Registry. Left Ventricular Ejection Fraction 1 Year After Acute Myocardial Infarction Identifies the Benefits of the Long-Term Use of  $\beta$ -Blockers: Analysis of Data From the KAMIR-NIH Registry. *Circ Cardiovasc Interv.* 2021 Apr;14(4):e010159. doi: 10.1161/CIRCINTERVENTIONS.120.010159.

Kim M, Park KW, Lee HS, Ki YJ, **Kang J**, Kim CH, Han JK, Yang HM, Kang HJ, Koo BK, Kim HS. The validation of the dual antiplatelet therapy score in East Asians receiving percutaneous coronary intervention with exclusively second generation drug-eluting stents. *Catheter Cardiovasc Interv.* 2021 Sep;98(3):E332-E341. doi: 10.1002/ccd.29682. Epub 2021 Apr 5.

Kwon S, Jung JH, Choi EK, Lee SW, Park J, Lee SR, **Kang J**, Han K, Park KW, Oh S, Lip GYH. Impact of Non-Vitamin K Antagonist Oral Anticoagulants on the Change of Antithrombotic Regimens in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. *Korean Circ J.* 2021 May;51(5):409-422. doi: 10.4070/kcj.2020.0407. Epub 2021 Jan 25.

Shin ES, Jun EJ, Han JK, Kong MG, **Kang J**, Zheng C, Garg S, Choi YJ, Bae JW, Chun KJ, Kim DI, Rha SW, Lee SY, Rhew JY, Woo SI, Lee HC, Jeong JO, Yang HM, Park KW, Kang HJ, Koo BK, Chae IH, Kim HS. Sex-related impact on clinical outcomes of patients treated with drug-eluting stents according to clinical presentation: Patient-level pooled analysis from the GRAND-DES registry. *Cardiol J.* 2021 Feb 26. doi: 10.5603/CJ.a2021.0008. Online ahead of print.

**Kang J\***, Park KW, Lee HS, Zheng C, Rhee TM, Ki YJ, Chang M, Han JK, Yang HM, Kang HJ, Koo BK, Kim HS. Relative Impact of Clinical Risk Versus Procedural Risk on Clinical Outcomes After Percutaneous Coronary Intervention. *Circ Cardiovasc Interv.* 2021 Feb;14(2):e009642. doi: 10.1161/CIRCINTERVENTIONS.120.009642. Epub 2021 Feb 5.

**Lee HS\***, **Kang J\***, Park KW, Ki YJ, Chang M, Han JK, Yang HM, Kang HJ, Koo BK, Kim HS. Procedural optimization of drug-coated balloons in the treatment of coronary artery disease. *Catheter Cardiovasc Interv.* 2021 Jul 1;98(1):E43-E52. doi: 10.1002/ccd.29492. Epub 2021 Jan 25.

\* Equal contribution

Oh GC, Park KW, Kang J, Han JK, Yang HM, Kang HJ, Koo BK, Kim HS. Association of Side-Branch Treatment and Patient Factors in Left Anterior Descending Artery True Bifurcation Lesions: Analysis from the GRAND-DES Pooled Registry. *J Interv Cardiol.* 2020 Dec 27;2020:8858642. doi: 10.1155/2020/8858642. eCollection 2020.



Lee MS\*, **Kang J\***, Park KW, Cho H, Lee HS, Han JK, Yang HM, Kang HJ, Koo BK, Kim HS. Percutaneous treatment of unprotected left main disease with thin strut durable polymer or early-generation thicker strutted and coated bioabsorbable polymer drug-eluting stents in a large-scale registry. *Cardiovasc Revasc Med.* 2020 Dec 31:S1553-8389(20)30820-4. doi: 10.1016/j.carrev.2020.12.034. Online ahead of print.

\* Equal contribution

Hwang HY, Paeng JC, **Kang J**, Jang MJ, Kim KB. Relation between functional coronary artery stenosis and graft occlusion after coronary artery bypass grafting. *J Thorac Cardiovasc Surg.* 2021 Mar;161(3):1010-1018.e1. doi: 10.1016/j.jtcvs.2020.11.072. Epub 2020 Dec 1.

Kim CH, Rhee TM, Woo Park K, Soon Park C, **Kang J**, Han JK, Yang HM, Kang HJ, Koo BK, Kim HS. Association Between Low Muscle Mass and Prognosis of Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. *J Am Heart Assoc.* 2021 Jan 5;10(1):e018554. doi: 10.1161/JAHA.120.018554. Epub 2020 Dec 29.

Ki YJ, Kang J, Lee HS, Chang M, Han JK, Yang HM, Park KW, Kang HJ, Koo BK, Kim HS. Optimal Oversizing Index Depending on Valve Type and Leakage-Proof Function for Preventing Paravalvular Leakage after Transcatheter Aortic Valve Implantation. *J Clin Med.* 2020 Dec 4;9(12):3936. doi: 10.3390/jcm9123936.

**Kang J\***, Yun JP, Ki YJ, Lee HS, Han JK, Yang HM, Park KW, Kang HJ, Koo BK, Kim HS. A New Hemodynamic Index Predicting Paravalvular Regurgitation After TAVR: Dicrotic AR Index. *JACC Cardiovasc Interv.* 2020 Nov 23;13(22):2711-2713. doi: 10.1016/j.jcin.2020.07.029.

Kim HS\*, **Kang J\***, Hwang D, Han JK, Yang HM, Kang HJ, Koo BK, Kim SY, Park KH, Rha SW, Shin WY, Lim HS, Park K, Park KW; HOST-REDUCE-POLYTECH-ACS Trial Investigators. Durable Polymer Versus Biodegradable Polymer Drug-Eluting Stents After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome: The HOST-REDUCE-POLYTECH-ACS Trial. *Circulation.* 2021 Mar 16;143(11):1081-1091.

\* Equal contribution

Lee HS, **Kang J\***. Renin-Angiotensin System Blockade in Acute Myocardial Infarction: Is There a Winner? *Korean Circ J.* 2020 Nov;50(11):995-997. doi: 10.4070/kcj.2020.0398.

Park J, Choi EK, Han KD, Kim B, Choi YJ, Lee SR, **Kang J**, Cha MJ, Park KW, Oh S, Lip GYH. Outcomes in relation to antithrombotic therapy among patients with atrial fibrillation after percutaneous coronary intervention. PLoS One. 2020 Oct 15;15(10):e0240161. doi: 10.1371/journal.pone.0240161. eCollection 2020.

Park J, Han JK, **Kang J**, Chae IH, Lee SY, Choi YJ, Rhew JY, Rha SW, Shin ES, Woo SI, Lee HC, Chun KJ, Kim DI, Jeong JO, Bae JW, Yang HM, Park KW, Kang HJ, Koo BK, Kim HS. Optimal Dose and Type of  $\beta$ -blockers in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. Am J Cardiol. 2020 Dec 15;137:12-19. doi: 10.1016/j.amjcard.2020.09.044. Epub 2020 Sep 28.

Lee HS, Park KW, **Kang J**, Ki YJ, Chang M, Han JK, Yang HM, Kang HJ, Koo BK, Kim HS. Sarcopenia Index as a Predictor of Clinical Outcomes in Older Patients with Coronary Artery Disease. J Clin Med. 2020 Sep 27;9(10):3121. doi: 10.3390/jcm9103121.

Kim HS\*, **Kang J\***, Hwang D, Han JK, Yang HM, Kang HJ, Koo BK, Rhew JY, Chun KJ, Lim YH, Bong JM, Bae JW, Lee BK, Park KW; HOST-REDUCE-POLYTECH-ACS investigators. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial. Lancet. 2020 Aug 28:S0140-6736(20)31791-8. doi: 10.1016/S0140-6736(20)31791-8.

\* equal contribution

**Kang J\***, Ahn H, Lee HS, Cho HJ. Still a Long Way to Go in Treating Cardiogenic Shock in Acute Myocardial Infarction. Circ J. 2020 Aug 25;84(9):1461-1463. doi: 10.1253/circj.CJ-20-0765.

Park J, Han JK, Chang M, Ki YJ, **Kang J**, Yang HM, Cho HJ, Park KW, Kang HJ, Koo BK, Kim HS. Impact of Intensive Glucose Control in Patients with Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: 3-Year Clinical Outcomes. J Clin Med. 2020 Aug 1;9(8):E2464. doi: 10.3390/jcm9082464.

Cho H, **Kang J**, Kim HS, Park KW. Ethnic Differences in Oral Antithrombotic Therapy. Korean Circ J. 2020 Aug;50(8):645-657. doi: 10.4070/kcj.2020.0098.

Zheng C\*, **Kang J\***, Yang HM, Han JK, Park KW, Kang HJ, Koo BK, Kim HS. Safety and Efficacy of Glycoprotein IIb/IIIa Inhibitors in Patients With Acute Myocardial Infarction in the Presence of

Intracoronary Thrombus: An Analysis From the Grand Drug-eluting Stent Registry. Clin Ther. 2020 May;42(5):954-958.e6.

\* equal contribution

Ki YJ, Park KW, **Kang J**, Kim CH, Han JK, Yang HM, Kang HJ, Koo BK, Kim HS. Safety and Efficacy of Second-Generation Drug-Eluting Stents in Real-World Practice: Insights from the Multicenter Grand-DES Registry. J Interv Cardiol. 2020 Feb 26;2020:3872704. doi:10.1155/2020/3872704.

Ki YJ\*, **Kang J\***, Park J, Han JK, Yang HM, Park KW, Kang HJ, Koo BK, Kim HS. Efficacy and Safety of Long-Term and Short-Term Dual Antiplatelet Therapy: A Meta-Analysis of Comparison between Asians and Non-Asians. J Clin Med. 2020 Feb 28;9(3):652. doi: 10.3390/jcm9030652.

\* equal contribution

Palmerini T, Chakravarty T, Saia F, Bruno AG, Bacchi-Reggiani ML, Marrozzini C, Patel C, Patel V, Testa L, Bedogni F, Ancona M, Montorfano M, Chieffo A, Olivares P, Bartorelli AL, Buscaglia A, Porto I, Nickenig G, Grube E, Sinning JM, De Carlo M, Petronio AS, Barbanti M, Tamburino C, Iadanza A, Burzotta F, Trani C, Fraccaro C, Tarantini G, Aranzulla TC, De Benedictis M, Pagnotta P, Stefanini GG, Miura M, Taramasso M, **Kang J**, Kim HS, Codner P, Kornowski R, Pelliccia F, Vignali L, Taglieri N, Ghetti G, Leone A, Galiè N, Makkar R. Coronary Protection to Prevent Coronary Obstruction During TAVR: A Multicenter International Registry. JACC Cardiovasc Interv. 2020 Mar 23;13(6):739-747.

Lee SH, Kim HK, Jeong MH, Yasuda S, Honda S, Jeong YH, Lee JM, Hahn JY, **Kang J**, Chae SC, Seong IW, Park JS, Chae JK, Hur SH, Cha KS, Kim HS, Seung KB, Rha SW, Hwang JY, Choi DJ, Oh SK, Kim SS, Park TK, Yang JH, Song YB, Choi SH, Gwon HC; KAMIR, JAMIR, and SMART-DATE Investigators. Practical Guidance for P2Y12 Inhibitors in Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention. Eur Heart J Cardiovasc Pharmacother. 2020 Jan 24:pvaa005.

**Kang J\***, Zheng C, Park KW, Park J, Rhee T, Lee HS, Han JK, Yang HM, Kang HJ, Koo BK, Kim HS. Complete Revascularization of Multivessel Coronary Artery Disease Does Not Improve Clinical Outcome in ST-Segment Elevation Myocardial Infarction Patients with Reduced Left Ventricular Ejection Fraction. J Clin Med. 2020 Jan 15;9(1):232. doi: 10.3390/jcm9010232.

Zheng C\*, **Kang J\***, Park KW, Han JK, Yang HM, Kang HJ, Koo BK, Kim HS. The Predictors of Target Lesion Revascularization and Rate of In-Stent Restenosis in the Second-Generation Drug-Eluting Stent Era. J Interv Cardiol. 2019 Jul 1;2019:3270132.

\* equal contribution

Jeon WK, Park J, Koo BK, Suh M, Yang S, Kim HY, Lee JM, Kim KJ, Choi JH, Lim HS, Paeng JC, Hwang D, Kim HS, Zhang J, **Kang J**, Han JK, Yang HM, Park KW. Anatomical Attributes of Clinically Relevant Diagonal Branches in Patients with Left Anterior Descending Coronary Artery Bifurcation Lesions. *EuroIntervention*. 2019 Nov 12;EIJ-D-19-00534. doi: 10.4244/EIJ-D-19-00534.

**Kang J\***, Han JK, Kang DY, Zheng C, Yang HM, Park KW, Kang HJ, Koo BK, Kim HS. SYNTAX Score and SYNTAX Score II Can Predict the Clinical Outcomes of Patients with Left Main and/or 3-Vessel Disease Undergoing Percutaneous Coronary Intervention in the Contemporary Cobalt-Chromium Everolimus-Eluting Stent Era. *Korean Circ J*. 2020 Jan;50(1):22-34. doi: 10.4070/kcj.2019.0097.

Kong MG, Han JK, **Kang J**, Zheng C, Yang HM, Park KW, Kang HJ, Koo BK, Chae IH, Kim HS; Collaborators. Clinical outcomes of long stent in the drug-eluting stent era: patient-level pooled analysis from the GRAND-DES registry. *EuroIntervention*. 2019 Sep 24;EIJ-D19-00296. doi: 10.4244/EIJ-D-19-00296.

**Hwang D\***, **Kang J\***, Yang HM, Yang S, Park J, Han JK, Kang HJ, Koo BK, Kim HS. Better Prognosis After Complete Revascularization Using Contemporary Coronary Stents in Patients With Chronic Kidney Disease. *Circ Cardiovascular intervention* 2019 Aug;12(8):e007907. doi: 10.1161

\* equal contribution

Kim CH, Park KW, **Kang J**, Park BE, Cha KS, Rhew JY, Jeon HK, Shin ES, Oh JH, Jeong MH, Kim S, Hwang KK, Yoon JH, Lee SY, Park TH, Moon KW, Kwon HM, Hur SH, Ryu JK, Lee BR, Park YW, Chae IH, Kim HS; HOST-ASSURE Investigators. Long-Term Comparison of Platinum Chromium Everolimus-Eluting Stent vs. Cobalt Chromium Zotarolimus-Eluting Stent 3 Year Outcomes From the HOST-ASSURE Randomized Clinical Trial. *Circ J*. 2019 Jun 25;83(7):1489-1497. doi: 10.1253/circj.CJ-18-1303.

**Kang J\***, Park KW, Ki YJ, Park J, Rhee T, Kim CH, Han JK, Yang HM, Kang HJ, Koo BK, Nakamura M, Hamasaki T, Yokoi H, Cohen D, Kim HS. Development and Validation of an Ischemic and Bleeding Risk Evaluation Tool in East Asian Patients Receiving Percutaneous Coronary Intervention. *Thromb Haemost*. 2019 Jul;119(7):1182-1193. doi: 10.1055/s-0039-1688792.

Park J, Choi EK, Han KD, Choi YJ, Lee SR, Cha MJ, **Kang J**, Park KW, Oh S, Lip GYH. Antithrombotic Therapy in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention During 2-Year Follow-Up, from a Nationwide Population Study. *Am J Cardiol* 2019 Jun 15;123(12):1921-1926. doi: 10.1016/j.amjcard.2019.03.024.

**Kang J\***, **Chun EJ\***, Park HJ, Cho YS, Park JJ, Kang SH, Cho YJ, Yoon YE, Oh IY, Yoon CH, Suh JW, Youn TJ, Chae IH, Choi DJ. Clinical and Computed Tomography Angiographic Predictors of Coronary Lesions That Later Progressed to Chronic Total Occlusion. *JACC cardiovascular imaging* 2019 Nov;12(11 Pt 1):2196-2206. doi: 10.1016/j.jcmg.2018.12.026. Epub 2019 Feb 13.

\* equal contribution

Park J, Choi EK, Han KD, Choi YJ, Lee E, Choe W, Lee SR, Cha MJ, Lim WH, **Kang J**, Park KW, Oh S, Lip GYH. Temporal trends in prevalence and antithrombotic treatment among Asians with atrial fibrillation undergoing percutaneous coronary intervention: A nationwide Korean population-based study. *PLoS One*. 2019 Jan 15;14(1):e0209593. doi: 10.1371

**Kang J\***, Park KW, Palmerini T, Stone GW, Lee MS, Colombo A, Chieffo A, Feres F, Abizaid A, Bhatt DL, Valgimigli M, Hong MK, Jang Y, Gilard M, Morice MC, Park DW, Park SJ, Jeong YH, Park J, Koo BK, Kim HS.acial Differences in Ischaemia/Bleeding Risk Trade-Off during Anti-Platelet Therapy: Individual Patient Level Landmark Meta-Analysis from Seven RCTs. *Thromb Haemost*. 2019 Jan;119(1):149-162. doi: 10.1055/s-0038-1676545.

Rhee TM, Park KW, Kim CH, **Kang J**, Han JK, Yang HM, Kang HJ, Koo BK, Kim HS. Dual Antiplatelet Therapy Duration Determines Outcome After 2- But Not 1-Stent Strategy in Left Main Bifurcation Percutaneous Coronary Intervention. *JACC Cardiovasc Interv*. 2018 Dec 24;11(24):2453-2463. doi: 10.1016

**Kang J\***, Cho HJ, Lee HY, Lee S, Park SK, Lee SE, Kim JJ, Jeon ES, Chae SC, Baek SH, Kang SM, Choi DJ, Yoo BS, Kim KH, Cho MC, Oh BH. Effects of Widespread Inotrope Use in Acute Heart Failure Patients. *J Clin Med*. 2018 Oct 18;7(10):368. doi: 10.3390

**Kang J\***, Kim HS. Bioresorbable Vascular Scaffolds: Is the Light Fading at the End of the Tunnel? - Reply. *Circ J*. 2018 Oct 25;82(11):2928. doi: 10.1253

**Kang J\***, Kim HS. The Evolving Concept of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: Focus on Unique Feature of East Asian and "Asian Paradox". *Korean Circ J*. 2018 Jul;48(7):537-551. doi: 10.4070/kcj.2018.0166.

**Kang J\***, Park KW, Lee MS, Zheng C, Han JK, Yang HM, Kang HJ, Koo BK, Kim HS. The natural course of nonculprit coronary artery lesions; analysis by serial quantitative coronary angiography. *BMC*

Cardiovasc Disord. 2018 Jun 28;18(1):130. doi: 10.1186

**Kang J\***, Koo BK, Hu X, Lee JM, Hahn JY, Yang HM, Shin ES, Nam CW, Doh JH, Lee BK, Ahn C, Wang J, Tahk SJ. Comparison of Fractional Flow Reserve And Intravascular ultrasoundguided Intervention Strategy for Clinical Outcomes in Patients with Intermediate Stenosis (FLAVOUR): Rationale and design of a randomized clinical trial. Am Heart J. 2018 May;199:7-12. doi: 10.1016/j.ahj.2017.11.001.

**Kang J\***, Park JJ, Cho YJ, Oh IY, Park HA, Lee SE, Kim MS, Cho HJ, Lee HY, Choi JO, Hwang KK, Kim KH, Yoo BS, Kang SM, Baek SH, Jeon ES, Kim JJ, Cho MC, Chae SC, Oh BH, Choi DJ. Predictors and Prognostic Value of Worsening Renal Function During Admission in HFpEF Versus HFrEF: Data From the KorAHF (Korean Acute Heart Failure) Registry. J Am Heart Assoc. 2018 Mar 13;7(6):e007910. doi: 10.1161/JAHA.117.007910.

**Kang J\***, Han JK\*, Ahn Y, Chae SC, Kim YJ, Chae IH, Hur SH, Seong IW, Chae JK, Cho MC, Seung KB, Jeong MH, Yang HM, Park KW, Kang HJ, Koo BK, Kim HS; investigators for Korea Acute Myocardial Infarction Registry-National Institute of Health (KAMIR-NIH). Third Generation P2Y12 Inhibitors in East Asian Acute Myocardial Infarction Patients: A Nationwide Prospective Multicentre Study. Thromb Haemost. 2018 Mar;118(3):591-600. doi: 10.1055/s-0038-1626697.

\* equal contribution

**Kang J\***, Kim HL, Lim WH, Seo JB, Zo JH, Kim MA, Kim SH. Relationship between brachialankle pulse wave velocity and invasively measured aortic pulse pressure. J Clin Hypertens (Greenwich). 2018 Mar;20(3):462-468. doi: 10.1111/jch.13200.

**Kang J\***, Kim HL, Seo JB, Lee JY, Moon MK, Chung WY. Endothelial function estimated by digital reactive hyperemia in patients with atherosclerotic risk factors or coronary artery disease. Heart Vessels. 2018 Jul;33(7):706-712. doi: 10.1007/s00380-018-1118-4.

**Kang J\***, Kim YC, Park JJ, Kim S, Kang SH, Cho YJ, Yoon YE, Oh IY, Yoon CH, Suh JW, Cho YS, Youn TJ, Chae IH, Choi DJ. Increased epicardial adipose tissue thickness is a predictor of new-onset diabetes mellitus in patients with coronary artery disease treated with highintensity statins. Cardiovasc Diabetol. 2018 Jan 11;17(1):10. doi: 10.1186/s12933-017-0650-3.

**Kang J\***, Kim HS. Where Are the Secrets of Increased Thrombosis and Aneurysm Formation With the Current Bioresorbable Vascular Scaffolds Hidden? - Reply. Circ J. 2018 Jan 25;82(2):609-610. doi: 10.1253/circj.CJ-17-1354.

**Kang J\***, Park KW, Kim HS. How far have we come with bioresorbable vascular scaffolds, and where should we go? *Cardiovasc Diagn Ther.* 2017 Jun;7(Suppl 2):S86-S90. doi: 10.21037/cdt.2017.01.11.

**Kang J\***, Han JK, Yang HM, Park KW, Kang HJ, Koo BK, Kim HS. Bioresorbable Vascular Scaffolds - Are We Facing a Time of Crisis or One of Breakthrough? *Circ J.* 2017 Jul 25;81(8):1065-1074. doi: 10.1253/circj.CJ-17-0152.

**Kang J\***, Kim TW, Hur J, Kim HS. Strategy to Prime the Host and Cells to Augment Therapeutic Efficacy of Progenitor Cells for Patients with Myocardial Infarction. *Front Cardiovasc Med.* 2016 Nov 24;3:46. eCollection 2016.

**Kang J\***, Jeon KH, Kim SW, Park JJ, Yoon CH, Suh JW, Cho YS, Youn TJ, Chae IH, Choi DJ. Evolution of nonculprit coronary atherosclerotic plaques assessed by serial virtual histology intravascular ultrasound in patients with ST-segment elevation myocardial infarction and chronic total occlusion. *Coron Artery Dis.* 2016 Dec;27(8):650-657.

Lee JM\*, **Kang J\***, Lee E, Hwang D, Rhee TM, Park J, Kim HL, Lee SE, Han JK, Yang HM, Park KW, Na SH, Kang HJ, Koo BK, Kim HS. Chronic Kidney Disease in the Second-Generation Drug-Eluting Stent Era: Pooled Analysis of the Korean Multicenter Drug-Eluting Stent Registry. *JACC Cardiovasc Interv.* 2016 Oct 24;9(20):2097-2109.

**\* equal contribution**

Lewis KM, Munske GR, Byrd SS, **Kang J**, Cho HJ, Ríos E, Kang C. Characterization of Post-Translational Modifications to Calsequestrins of Cardiac and Skeletal Muscle. *Int J Mol Sci.* 2016 Sep 13;17(9).

**Kang J\***, Park KW, Han JK, Yang HM, Kang HJ, Koo BK, Kim HS. Usefulness of the Baseline Syntax Score to Predict 3-Year Outcome After Complete Revascularization by Percutaneous Coronary Intervention. *Am J Cardiol.* 2016 Jun 15.

Han JK, Kim BK, Won JY, Shin Y, Choi SB, Hwang I, **Kang J**, Lee HJ, Koh SJ, Lee J, Hur J, Cho HJ, Chae IH, Oh BH, Park YB, Kim HS. Interaction between platelets and endothelial progenitor cells via LPA-Edg-2 axis is augmented by PPAR- $\delta$  activation. *J Mol Cell Cardiol.* 2016 Jun 3;97:266-277.

**Kang J\***, Hur J\*, Kang JA\*, Lee HS, Jung H, Choi JI, Lee H, Kim YS, Ahn Y, Kim HS. Priming mobilized peripheral blood mononuclear cells with the "activated platelet supernatant" enhances the efficacy of cell therapy for myocardial infarction of rats. *Cardiovasc Ther.* 2016 Aug;34(4):245-53.

**Kang J\***, Park J\*, Lee JM, Park JJ, Choi DJ. The effects of erythropoiesis stimulating therapy for anemia in chronic heart failure: A meta-analysis of randomized clinical trials. *Int J Cardiol.* 2016 Sep 1;218:12-22.

Hur J, Choi JI, Lee H, Nham P, Kim TW, Chae CW, Yun JY, Kang JA, **Kang J**, Lee SE, Yoon CH, Boo K, Ham S, Roh TY, Jun JK, Lee H, Baek SH, Kim HS. CD82/KAI1 Maintains the Dormancy of Long-Term Hematopoietic Stem Cells through Interaction with DARC-Expressing Macrophages. *Cell Stem Cell.* 2016 Apr 7;18(4):508-21.

**Kang J\***, Cho YS, Kim SW, Park JJ, Yoon YE, Oh IY, Yoon CH, Suh JW, Youn TJ, Chae IH, Choi DJ. Intravascular Ultrasound and Angiographic Predictors of In-Stent Restenosis of Chronic Total Occlusion Lesions. *PLoS One.* 2015 Oct 14;10(10):e0140421.

Lee JM, Hahn JY, **Kang J**, Park KW, Chun WJ, Rha SW, Yu CW, Jeong JO, Jeong MH, Yoon JH, Jang Y, Tahk SJ, Gwon HC, Koo BK, Kim HS. Differential Prognostic Effect Between First- and Second-Generation Drug-Eluting Stents in Coronary Bifurcation Lesions: Patient-Level Analysis of the Korean Bifurcation Pooled Cohorts. *JACC Cardiovasc Interv.* 2015 Aug 24;8(10):1318-31.

Kang HJ, Kang WS, Hong MH, Choe N, Kook H, Jeong HC, **Kang J**, Hur J, Jeong MH, Kim YS, Ahn Y. Involvement of miR-34c in high glucose-insulted mesenchymal stem cells leads to inefficient therapeutic effect on myocardial infarction. *Cell Signal.* 2015 Nov;27(11):2241-51.

Kim HJ, Kim KI, Cho YS, **Kang J**, Park JJ, Oh IY, Yoon CH, Suh JW, Youn TJ, Chae IH, Choi DJ. The effect of admission at weekends on clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome and its contributing factors. *J Korean Med Sci.* 2015 Apr;30(4):414-25.

Lee JM, Park J, **Kang J**, Jeon KH, Jung JH, Lee SE, Han JK, Kim HL, Yang HM, Park KW, Kang HJ, Koo BK, Kim HS. Comparison among drug-eluting balloon, drug-eluting stent, and plain balloon angioplasty for the treatment of in-stent restenosis: a network meta-analysis of 11 randomized, controlled trials. *JACC Cardiovasc Interv.* 2015 Mar;8(3):382-94.

Lee JM, Park J, **Kang J**, Jeon KH, Jung JH, Lee SE, Han JK, Kim HL, Yang HM, Park KW, Kang HJ,



Koo BK, Kim SH, Kim HS. The efficacy and safety of mechanical hemodynamic support in patients undergoing high-risk percutaneous coronary intervention with or without cardiogenic shock: Bayesian approach network meta-analysis of 13 randomized controlled trials. *Int J Cardiol.* 2015 Apr 1;184:36-46.

**Kang J\***, Yun JY\*, Hur J, Kang JA, Choi JI, Ko SB, Lee J, Kim JY, Hwang IC, Park YB, Kim HS., Erythropoietin priming improves the vasculogenic potential of G-CSF mobilized human peripheral blood mononuclear cells. *Cardiovasc Res.* 2014 Oct 1;104(1):171-8

**Kang J\***, Hur J, Kang JA, Yun JY, Choi JI, Ko SB, Lee CS, Lee J, Han JK, Kim HK, Kim HS., Activated platelet supernatant can augment the angiogenic potential of human peripheral blood stem cells mobilized from bone marrow by G-CSF. *J Mol Cell Cardiol.* 2014 Oct;75:64-75.

Park KW\*, **Kang J\***, Kang SH, Ahn HS, Kang HJ, Koo BK, Chae IH, Youn TJ, Oh BH, Park YB, Kandzari D, Kim HS., The impact of residual coronary lesions on clinical outcomes after percutaneous coronary intervention: Residual SYNTAX score after percutaneous coronary intervention in patients from the Efficacy of Xience/Promus versus Cypher in rEducating Late Loss after stENTing (EXCELLENT) registry. *Am Heart J.* 2014 Mar;167(3):384-39

\* equal contribution

Park KW\*, **Kang J\***, Kang SH, Ahn HS, Lee HY, Kang HJ, Koo BK, Chae IH, Youn TJ, Oh BH, Park YB, Kandzari DE, Kim HS., Usefulness of the SYNTAX and clinical SYNTAX scores in predicting clinical outcome after unrestricted use of sirolimus- and everolimus-eluting Stents., *Circ J.* 2013;77(12):2912-21.

\* equal contribution

**Kang J\***, Cho YS, Song HY, Kim HJ, Oh IY, Yoon CH, Suh JW, Kim KI, Chung WY, Youn TJ, Chae IH, Choi DJ. Impact of Anticoagulation on Coronary Flow in Patients With Non-ST Elevation Acute Coronary Syndrome. *Clin Appl Thromb Hemost.* 2015 Jan;21(1):48-57.

Park KW\*, **Kang J\***, Park JJ, Yang HM, Kwon YW, Lee HY, Kang HJ, Koo BK, Oh BH, Park YB, Kim HS. Thiazolidinedione usage is associated with decreased response to clopidogrel in DM patients. *Int J Cardiol.* 2013 Sep 20;168(1):608-10

\* equal contribution

Chung WY\*, **Kang J\***, Cho YS, Park HJ, Yang HM, Seo JB, Suh JW, Kim KI, Youn TJ, Kim SH, Chae

IH, Zo JH, Kim MA, Choi DJ., A randomized, prospective, two-center comparison of sirolimus-eluting stent and zotarolimus-eluting stent in acute ST-elevation myocardial infarction: the SEZE trial., Chin Med J (Engl). 2012 Oct;125(19):3373-81.

\* equal contribution

Park KW\*, **Kang J\***, Park JJ, Yang HM, Lee HY, Kang HJ, Koo BK, Oh BH, Park YB, Kim HS., Amlodipine, clopidogrel and CYP3A5 genetic variability: effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention., Heart. 2012 Sep;98(18):1366-72.

\* equal contribution